345
Participants
Start Date
February 29, 2016
Primary Completion Date
March 31, 2025
Study Completion Date
March 31, 2025
Pittsburgh Compound B [11C]-PIB
This is a cross-sectional study of patients with various forms of cognitive impairment and a healthy control group for comparison. Brain amyloid PET scans using the radioligand Pittsburgh Compound B \[11C\]-PIB, which is not yet approved for clinical use in Canada, will be performed in all subjects.
RECRUITING
Sunnybrook Health Sciences Centre, Toronto
RECRUITING
St. Michael's Hospital, Toronto
RECRUITING
University Health Network, Toronto
ENROLLING_BY_INVITATION
Baycrest Health Sciences, Toronto
RECRUITING
Centre for Addiction and Mental Health (CAMH), Toronto
Collaborators (1)
Brain Canada
OTHER
Weston Brain Institute
OTHER
GE Healthcare
INDUSTRY
University Health Network, Toronto
OTHER
Centre for Addiction and Mental Health
OTHER
Baycrest
OTHER
Unity Health Toronto
OTHER
Kensington Eye Institute
OTHER
Sunnybrook Health Sciences Centre
OTHER